BioXcel Therapeutics
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, BioXcel Therapeutics sits in the top decile of US sponsors by registered trial count (#1,049 of 15,742 sponsors by registered trial count).
BioXcel Therapeutics: 13 sponsored US clinical trials, 1 recruiting.
BioXcel Therapeutics sponsors 13 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 9 completed. 6 of these trials are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Schizoaffective Disorder, with 2 trials.
Top-decile sponsor footprint
BioXcel Therapeutics ranks in the top decile of sponsors by registered trial count (#1,049 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
9 of 11 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (81.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
13 total, page 1 of 1
Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder
NCT05025605
Assessment of Acute Psychomotor Agitation Measures Associated With Schizophrenia and Bipolar Disorder
NCT07116694
Tachyphylaxis, Tolerance, & Withdrawal Post Treatment With Igalmi for Agitation in Schizophrenia or Bipolar Disorder
NCT06041646
Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY III)
NCT05665088
Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III)
NCT05658510
Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY II)
NCT05271552
An Efficacy, and Safety Study Of BXCL501 For The Treatment Of Agitation Associated With Dementia
NCT05276830
Dexmedetomidine in the Treatment of Symptoms Of Acute Opioid Withdrawal
NCT04470050
Dexmedetomidine in the Treatment of Agitation Associated With Bipolar Disorder
NCT04276883
Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia
NCT04268303
Sub-Lingual Dexmedetomidine in Agitation Associated With Dementia
NCT04251910
Sub-Lingual Dexmedetomidine in Agitation Associated With Schizophrenia
NCT04010305
A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype.
NCT03910660
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
| Phase 2 | 2 |
| Phase 3 | 5 |
| Phase 4 | 1 |
What is open in the BioXcel Therapeutics pipeline
1 recruiting of 13 indexed (8% open); 9 completed (69%).
Phase mix: 6 late (III/IV) vs 7 early (I/II) (balanced across stages).
Top condition: Schizoaffective Disorder (2 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
BioXcel Therapeutics: open-pipeline peers nationwide
Peers matched on 13 registered trials and 8% open enrollment, not the therapeutic-area sidebar.
BioXcel Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 13 trials (± recruiting share)
- Adaptimmune · 13 trials · 0% recruiting
- Agennix · 13 trials · 0% recruiting
- Akili Interactive Labs · 13 trials · 0% recruiting
- Alumis · 13 trials · 8% recruiting
Sponsors near 8% open enrollment (± trial volume)
- Andrei Iagaru · 8% recruiting · 13 trials
- Corporal Michael J. Crescenz VA Medical Center · 8% recruiting · 13 trials
- Fresenius Medical Care North America · 8% recruiting · 13 trials
- LG Chem · 8% recruiting · 13 trials
Related
What to do with this BioXcel Therapeutics page
13 registered trials is a research-attention snapshot, not an endorsement of BioXcel Therapeutics or any single study.
- 1 of BioXcel Therapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Schizoaffective Disorder is the condition BioXcel Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Schizoaffective Disorder trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
BioXcel Therapeutics pipeline card: 13 registered trials from official public datasets.Report a data error.